chartexchange

CRISPR Therapeutics Reports $12.7 Million Revenue, Net Loss Per Share of $1. ...

GuruFocus | Nov 2, 2026 4:33 PM EST

Revenue of $12.7 million tops the $10.49 million analyst estimate, while the loss per share of $1.15 comes in wider than the projected $0.98 Related Stocks: CRSP ,

Read original article